Ratings by JPMorgan (David Low)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/9/2024 | ResMed | RMD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/9/2023 | ResMed | RMD | Upgrade | Overweight (Neutral) |
146.59 (183.42) |
25.12% | Details | |
| 5/1/2023 | ResMed | RMD | Maintain | Overweight (N/A) |
|
Details | ||
| 4/13/2023 | ResMed | RMD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2023 | ResMed | RMD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2023 | ResMed | RMD | Upgrade | Overweight (Neutral) |
214.00 (146.59) |
-31.5% | Details | |
| 8/12/2022 | ResMed | RMD | Downgrade | Neutral (Overweight) |
240.85 (183.42) |
-23.84% | Details | |
| 3/23/2022 | ResMed | RMD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/24/2022 | ResMed | RMD | Upgrade | Overweight (Neutral) |
235.16 (240.85) |
2.42% | Details | |
| 5/21/2021 | ResMed | RMD | Upgrade | Overweight (Neutral) |
198.75 (235.16) |
18.32% | Details | |
| 10/30/2020 | ResMed | RMD | Upgrade | Neutral (Underweight) |
179.51 (183.42) |
2.18% | Details |
